questionText: To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what arrangements are in place to monitor patient outcomes following the expanded use of abiraterone at earlier stages of prostate cancer; and whether those outcomes will be published on a national and regional basis.
answerText: Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prost...
heading: Prostate Cancer: Abiraterone